Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.

Authors

Hirva Mamdani

Indiana University, Indianapolis, IN

Hirva Mamdani , Bryan J. Schneider , Laith I. Abushahin , Thomas J Birdas , Kenneth Kesler , Ahran Lee , Heather Burney , Susan Perkins , Shadia Ibrahim Jalal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from big ten cancer research consortium study.

First Author: Hirva Mamdani

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

A phase II study of durvalumab following multimodality therapy for locally advanced esophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-ESO14-012 study.

First Author: Hirva Mansurali Mamdani

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Updated survival and early translational results from Big Ten Cancer Research Consortium Study.

First Author: Hirva Mamdani

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

First Author: John M. Varlotto